US Archives - Page 124 of 165 - European Medical Journal

Rheumatology’s Most Impactful Discoveries This Year

EXPERTS at the American College of Rheumatology (ACR) Convergence 2024 identified and showcased the most groundbreaking discoveries in the…

AI Tool Predicts Early Flare in Rheumatic Diseases

Rheumatic and musculoskeletal diseases (RMD) affect up to one-third of the UK population, are the number one cause of disability, and are…

Harnessing the Power of AI in Rheumatology

THIS year’s American College of Rheumatology (ACR) Convergence, which took place from Novemeber 14th–19th 2024 in Washington, D.C., saw…

Plant-Based Diet Impact on Gout: A Pilot Study

An unhealthy diet is an important modifiable risk factor for hyperuricemia and gout and is also associated with obesity and metabolic…

Boosting Prior Authorization with AI in Rheumatology

The prior authorization (PA) process in healthcare, while necessary for ensuring the medical necessity and cost-effectiveness of treatments, often results in significant delays. This study explores the potential of AI

Oral Healthcare Needs in Canadian Rheumatic Patients

Patients with autoimmune rheumatic diseases (RD) have a high prevalence of oral manifestations and/or oral side effects from…

Quality Improvement for Vasculitis Vaccination

Vasculitis is an umbrella term encompassing approximately 20 rare but serious diseases that are characterized by autoimmune inflammation…

Early Oseltamivir Treatment Reduces Mortality in Patients Hospitalized with Flu

Initiating oseltamivir treatment on the day of hospital admission significantly reduces the severity of illness and risk of death in adults hospitalized with influenza.

Blood Pressure Variability and Cognitive Decline in Older Adults

Findings revealed that higher blood pressure variability, particularly in systolic blood pressure, was associated with lower cognitive scores at the final follow-up.

Efficacy of Selpercatinib Beyond NSCLC Progression

Selpercatinib, a targeted RET kinase inhibitor, has demonstrated continued efficacy in treating RET fusion-positive non–small cell lung cancer (NSCLC) even after disease progression.